A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Clinical trial NCT02164513 · COMPLETED
Trial details
- NCT number
- NCT02164513
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-06-30
- Primary completion
- 2017-07-17
- Enrollment
- 10355
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.